An Open-label, Multicenter, Phase 2 Basket Study to Investigate the Efficacy, Safety, Pharmacokinetics and Pharmacodynamics of STI-3031 in Patients With Selected Relapsed or Refractory Solid Tumors
Latest Information Update: 29 Mar 2022
At a glance
- Drugs Danburstotug (Primary)
- Indications Solid tumours
- Focus Therapeutic Use
- Sponsors Sorrento Therapeutics
- 09 Mar 2022 Status changed from not yet recruiting to withdrawn prior to enrolment.
- 24 Mar 2021 New trial record